Published in J Control Release on February 20, 2011
Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol (2012) 1.87
Nonporous Silica Nanoparticles for Nanomedicine Application. Nano Today (2013) 1.04
Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano (2013) 0.93
Interference in autophagosome fusion by rare earth nanoparticles disrupts autophagic flux and regulation of an interleukin-1β producing inflammasome. ACS Nano (2014) 0.88
Nanoparticle Uptake: The Phagocyte Problem. Nano Today (2015) 0.84
Nanomaterials and autophagy: new insights in cancer treatment. Cancers (Basel) (2013) 0.83
Bio-active engineered 50 nm silica nanoparticles with bone anabolic activity: therapeutic index, effective concentration, and cytotoxicity profile in vitro. Toxicol In Vitro (2013) 0.82
Nanomaterials toxicity and cell death modalities. J Drug Deliv (2012) 0.82
Macrophage silica nanoparticle response is phenotypically dependent. Biomaterials (2015) 0.81
Macrophage-derived MCPIP1 mediates silica-induced pulmonary fibrosis via autophagy. Part Fibre Toxicol (2016) 0.79
Facilitating Translational Nanomedicine via Predictive Safety Assessment. Mol Ther (2017) 0.77
Differential Protein Adsorption and Cellular Uptake of Silica Nanoparticles Based on Size and Porosity. ACS Appl Mater Interfaces (2016) 0.76
Transcriptional responses of human aortic endothelial cells to nanoconstructs used in biomedical applications. Mol Pharm (2013) 0.76
Stress fibers, autophagy and necrosis by persistent exposure to PM2.5 from biomass combustion. PLoS One (2017) 0.75
Role of autophagy in cell-penetrating peptide transfection model. Sci Rep (2017) 0.75
Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet (2009) 14.06
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A (2007) 7.50
Ultrastructural analysis of the autophagic process in yeast: detection of autophagosomes and their characterization. J Cell Biol (1994) 5.41
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano (2008) 3.88
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc (2003) 2.69
In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano (2010) 2.30
The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials (2007) 2.16
Vesicular trafficking and autophagosome formation. Cell Death Differ (2009) 2.14
PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway. J Mol Cell Biol (2009) 2.00
Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett (2009) 1.97
Epithelial cells as phagocytes: apoptotic epithelial cells are engulfed by mammary alveolar epithelial cells and repress inflammatory mediator release. Cell Death Differ (2005) 1.93
Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. Exp Cell Res (2005) 1.87
Nanoparticles for bioimaging. Adv Colloid Interface Sci (2006) 1.83
Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci (2007) 1.77
Silica binding and toxicity in alveolar macrophages. Free Radic Biol Med (2007) 1.65
Incorporation of iron oxide nanoparticles and quantum dots into silica microspheres. ACS Nano (2008) 1.63
Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc (2010) 1.58
In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ Sci Technol (2007) 1.58
Macrophage responses to silica nanoparticles are highly conserved across particle sizes. Toxicol Sci (2008) 1.55
The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol (2008) 1.50
Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials (2010) 1.44
Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation. Nano Lett (2006) 1.43
Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking. FASEB J (2005) 1.37
Uptake of silica-coated nanoparticles by HeLa cells. J Nanosci Nanotechnol (2005) 1.36
Toxicity of luminescent silica nanoparticles to living cells. Chem Res Toxicol (2007) 1.32
Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. Swiss Med Wkly (2008) 1.12
Review: bioanalytical applications of biomolecule-functionalized nanometer-sized doped silica particles. Anal Chim Acta (2009) 1.11
Endocytosis of a single mesoporous silica nanoparticle into a human lung cancer cell observed by differential interference contrast microscopy. Anal Bioanal Chem (2008) 1.05
Gatekeeping layer effect: a poly(lactic acid)-coated mesoporous silica nanosphere-based fluorescence probe for detection of amino-containing neurotransmitters. J Am Chem Soc (2004) 1.01
pH- and photo-switched release of guest molecules from mesoporous silica supports. J Am Chem Soc (2009) 0.99
Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials. Chem Res Toxicol (2009) 0.89
Mesoporous silica-based nanomaterials for drug delivery: evaluation of structural properties associated with release rate. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.88
Sustained release from mesoporous nanoparticles: evaluation of structural properties associated with release rate. Curr Drug Deliv (2008) 0.85
Real-time imaging of tunable adenosine 5-triphosphate release from an MCM-41-type mesoporous silica nanosphere-based delivery system. Appl Spectrosc (2005) 0.83
Protein adsorption orientation in the light of fluorescent probes: mapping of the interaction between site-directly labeled human carbonic anhydrase II and silica nanoparticles. Biophys J (2005) 0.81
Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med (2005) 2.09
In vitro and in vivo evaluation of recombinant silk-elastinlike hydrogels for cancer gene therapy. J Control Release (2004) 1.53
Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: Influence of size, charge and fluorescent labeling. Pharm Res (2006) 1.51
Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano (2011) 1.47
Genetically engineered silk-elastinlike protein polymers for controlled drug delivery. Adv Drug Deliv Rev (2002) 1.46
Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. J Appl Toxicol (2010) 1.38
Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem (2007) 1.36
Swelling behavior of a genetically engineered silk-elastinlike protein polymer hydrogel. Biomaterials (2002) 1.36
Cellular uptake and cytotoxicity of silica nanotubes. Nano Lett (2008) 1.27
Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm Res (2007) 1.25
Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J Control Release (2002) 1.23
Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev (2005) 1.23
Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol Pharm (2008) 1.21
In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release (2012) 1.21
Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des (2006) 1.20
Molecular engineering of silk-elastinlike polymers for matrix-mediated gene delivery: biosynthesis and characterization. Mol Pharm (2005) 1.18
Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology (2011) 1.17
Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release (2005) 1.17
Genetically engineered polymers: status and prospects for controlled release. J Control Release (2004) 1.16
Silk-elastinlike recombinant polymers for gene therapy of head and neck cancer: from molecular definition to controlled gene expression. J Control Release (2009) 1.15
Solute diffusion in genetically engineered silk-elastinlike protein polymer hydrogels. J Control Release (2002) 1.13
Controlled release of plasmid DNA from a genetically engineered silk-elastinlike hydrogel. Pharm Res (2002) 1.11
Silk-elastinlike protein polymers for matrix-mediated cancer gene therapy. Adv Drug Deliv Rev (2010) 1.10
Genetic engineering of stimuli-sensitive silkelastin-like protein block copolymers. Biomacromolecules (2003) 1.10
Polymeric conjugates for drug delivery. Chem Mater (2012) 1.06
Guided Delivery of Polymer Therapeutics Using Plasmonic Photothermal Therapy. Nano Today (2012) 1.05
Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. Pharm Res (2010) 1.04
Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. J Control Release (2006) 1.04
Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm Res (2008) 1.01
Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery. J Control Release (2009) 1.00
Technetium-99m-Labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution. Pharm Res (2004) 0.99
Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS Nano (2012) 0.99
Surface Induced nanofiber growth by self-assembly of a silk-elastin-like protein polymer. Langmuir (2009) 0.98
HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv Drug Deliv Rev (2009) 0.98
Silk-elastinlike protein polymer hydrogels for localized adenoviral gene therapy of head and neck tumors. Biomacromolecules (2009) 0.98
Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS Nano (2012) 0.97
Characterization and real-time imaging of gene expression of adenovirus embedded silk-elastinlike protein polymer hydrogels. Mol Pharm (2008) 0.96
Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol (2006) 0.96
Recombinant protein-based polymers for advanced drug delivery. Chem Soc Rev (2012) 0.96
Genetic synthesis and characterization of pH- and temperature-sensitive silk-elastinlike protein block copolymers. J Biomed Mater Res (2002) 0.95
Biological evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment. J Drug Target (2011) 0.94
In vitro chondrogenesis of mesenchymal stem cells in recombinant silk-elastinlike hydrogels. Pharm Res (2007) 0.94
Charge affects the oral toxicity of poly(amidoamine) dendrimers. Eur J Pharm Biopharm (2013) 0.93
Template synthesis of multifunctional nanotubes for controlled release. J Control Release (2006) 0.93
Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano (2013) 0.93
Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation. J Control Release (2008) 0.93
G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J Control Release (2010) 0.93
Retracted Fabrication of highly uniform nanoparticles from recombinant silk-elastin-like protein polymers for therapeutic agent delivery. ACS Nano (2011) 0.93
Influence of polymer structure and biodegradation on DNA release from silk-elastinlike protein polymer hydrogels. Int J Pharm (2008) 0.92
Silk-elastin-like hydrogel improves the safety of adenovirus-mediated gene-directed enzyme-prodrug therapy. Mol Pharm (2010) 0.92
Noninvasive monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance imaging. Pharm Res (2009) 0.91
Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation. Bioconjug Chem (2010) 0.91
Comparison of silk-elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery. Int J Pharm (2011) 0.91
Silk-elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors. J Gene Med (2010) 0.90
Cationic PAMAM dendrimers disrupt key platelet functions. Mol Pharm (2012) 0.90
Influence of solute charge and hydrophobicity on partitioning and diffusion in a genetically engineered silk-elastin-like protein polymer hydrogel. Macromol Biosci (2010) 0.90
A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol Cancer Ther (2007) 0.90
PAMAM-camptothecin conjugate inhibits proliferation and induces nuclear fragmentation in colorectal carcinoma cells. Pharm Res (2010) 0.89
Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J Control Release (2004) 0.89
Synthesis and characterization of a matrix-metalloproteinase responsive silk-elastinlike protein polymer. Biomacromolecules (2013) 0.88
Gold nanorod mediated plasmonic photothermal therapy: a tool to enhance macromolecular delivery. Int J Pharm (2011) 0.88
Nanomechanical stimulus accelerates and directs the self-assembly of silk-elastin-like nanofibers. J Am Chem Soc (2011) 0.88
Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. Mol Pharm (2009) 0.88
Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. J Drug Target (2005) 0.87
Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Res (2003) 0.86
HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer. Pharm Res (2010) 0.85
Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy. Pharm Res (2009) 0.85
Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia. J Control Release (2013) 0.85
Macrophage targeted N-(2-hydroxypropyl)methacrylamide conjugates for magnetic resonance imaging. Mol Pharm (2006) 0.85
Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm (2011) 0.85
Plasmonic photothermal therapy increases the tumor mass penetration of HPMA copolymers. J Control Release (2012) 0.84
Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release (2011) 0.84
Evidence of oral translocation of anionic G6.5 dendrimers in mice. Mol Pharm (2013) 0.83
Recombinant biomaterials for pharmaceutical and biomedical applications. Pharm Res (2007) 0.81
Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors. Int J Pharm (2013) 0.80
In vivo methods of nanotoxicology. Methods Mol Biol (2012) 0.80
Kinetic analysis of the interaction between poly(amidoamine) dendrimers and model lipid membranes. Biochim Biophys Acta (2010) 0.79
Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin. Int J Pharm (2011) 0.79
Riboflavin-targeted polymer conjugates for breast tumor delivery. Pharm Res (2013) 0.78
HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation. Macromol Biosci (2008) 0.78
Transepithelial transport of PAMAM dendrimers across isolated rat jejunal mucosae in ussing chambers. Biomacromolecules (2014) 0.78
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. Int J Pharm (2013) 0.78
Direct observation of amyloid nucleation under nanomechanical stretching. ACS Nano (2013) 0.78
Thermal analysis of water in silk-elastinlike hydrogels by differential scanning calorimetry. Biomacromolecules (2004) 0.77
Mild Hyperthermia Induced by Gold Nanorod-Mediated Plasmonic Photothermal Therapy Enhances Transduction and Replication of Oncolytic Adenoviral Gene Delivery. ACS Nano (2016) 0.76
Sustained local delivery of oncolytic short hairpin RNA adenoviruses for treatment of head and neck cancer. J Gene Med (2014) 0.76
Materials for advanced drug delivery in the 21st century: a focus area for Advanced Drug Delivery Reviews. Adv Drug Deliv Rev (2008) 0.76
Transcriptional responses of human aortic endothelial cells to nanoconstructs used in biomedical applications. Mol Pharm (2013) 0.76
Directed patterning of the self-assembled silk-elastin-like nanofibers using a nanomechanical stimulus. Chem Commun (Camb) (2012) 0.76
In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer. Macromol Biosci (2014) 0.75
Advanced drug delivery: perspectives and prospects. Preface. Adv Drug Deliv Rev (2012) 0.75